Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy

Turk J Haematol. 2018 May 25;35(2):135-136. doi: 10.4274/tjh.2017.0448. Epub 2018 Feb 2.

Authors

Takashi Onaka¹, Tomoya Kitagawa¹, Chika Kawakami², Akihito Yonezawa¹

Affiliations

¹ Kokura Memorial Hospital, Clinic of Hematology, Kitakyushu, Fukuoka, Japan.
² University of Occupational and Environmental, Department of Dermatology, Fukuoka, Japan.

No abstract available

Keywords: Brentuximab vedotin Cutaneous ALCL..

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Brentuximab Vedotin
Erythema / complications
Erythema / drug therapy
Erythema / pathology
Female
Humans
Immunoconjugates / administration & dosage
Immunoconjugates / therapeutic use*
Lymphoma, Large-Cell, Anaplastic / complications
Lymphoma, Large-Cell, Anaplastic / drug therapy*
Lymphoma, Large-Cell, Anaplastic / pathology
Skin / drug effects
Skin / pathology
Skin Neoplasms / complications
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Antineoplastic Agents
Immunoconjugates
Brentuximab Vedotin